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Abstract
Background: Antiarrhythmic action of flecainide is based on sodium channel blockade. Beta1-adrenoceptor (b1AR)
activation induces sodium channel inhibition, too. The aim of the present study was to evaluate the impact of different b1AR
genotypes on antiarrhythmic action of flecainide in patients with structural heart disease and atrial fibrillation.
Methodology/Principal Findings: In 145 subjects, 87 with atrial fibrillation, genotyping was performed to identify the
individual b1AR Arg389Gly and Ser49Gly polymorphism. Resting heart rate during atrial fibrillation and success of flecainide-
induced cardioversion were correlated with b1AR genotype. The overall cardioversion rate with flecainide was 39%. The
Arg389Arg genotype was associated with the highest cardioversion rate (55.5%; OR 3.30; 95% CI; 1.34–8.13; p=0.003)
compared to patients with Arg389Gly (29.5%; OR 0.44; 95% CI; 0.18–1.06; p=0.066) and Gly389Gly (14%; OR 0.24; 95% CI
0.03–2.07; p=0.17) variants. The single Ser49Gly polymorphism did not influence the conversion rate. In combination,
patients with Arg389Gly-Ser49Gly genotype displayed the lowest conversion rate with 20.8% (OR 0.31; 95% CI; 0.10–0.93;
p=0.03). In patients with Arg389Arg variants the heart rate during atrial fibrillation was significantly higher (11062.7 bpm;
p=0.03 vs. other variants) compared to Arg389Gly (104.862.4 bpm) and Gly389Gly (96.965.8 bpm) carriers. The Arg389Gly-
Ser49Gly genotype was more common in patients with atrial fibrillation compared to patients without atrial fibrillation
(27.6% vs. 5.2%; HR 6.98; 95% CI; 1.99–24.46; p,0.001).
Conclusions: The b1AR Arg389Arg genotype is associated with increased flecainide potency and higher heart rate during
atrial fibrillation. The Arg389Gly-Ser49Gly genotype might be of predictive value for atrial fibrillation.
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Introduction
Flecainide is used for cardioversion in patients with recent onset
atrial fibrillation (AF). It has been successfully implemented for out-
of-hospital use as a pill-in-the-pocket approach in patients without
structural heart disease [1,2]. In patients with organic heart disease
our group recently reported that a single dosage of flecainide is not
harmful, but less efficient than in healthy subjects [3]. Only few
factors which might predict the success of flecainide in acute
cardioversion have been identified, yet. The duration of AF and the
extentofcardiacremodeling indiseasedheartmightbesuch factors.
The antiarrhythmic effect of flecainide is based on Na
+ current
(INa) inhibition [4]. Experimental data have shown that beta1-
adrenergic receptor (b1AR) stimulation causes an inhibition of INa,
too [5,6,7,8].
For the b1AR, 12 nucleotide polymorphisms (SNPs) have been
identified, but only two have being associated with possibly
functional relevance (for review see [9]). At position 389 (P389),
the putative stimulatory G-protein coupling domain of b1AR,
glycine (Gly389) is substituted by arginine (Arg389). The Arg389
variants exhibited higher basal adenyl cyclase activity than the
Gly389 variants [10,11]. In clinical experiments patients with
Arg389 allele exerted augmented cardiac contractile response to
catecholamines [12]. The second potential relevant polymorphism
is linked to the position 49 (P49) of b1AR, where serine (Ser49) is
substituted by glycine (Gly49) [10,13,14]. Ser49Gly b1AR is
considered to play a modulating role without affecting the agonist
binding and basal or maximal stimulated adenyl cyclase activity
[10,15,16].
In the present study we aimed to determine whether the two
SNPs P389 and P49 of b1AR are relevant in predicting AF,
antiarrhythmic drug therapy and flecainide-induced cardioversion
in patients with recent onset AF.
Methods
Ethics Statement
The study complies with the Declaration of Helsinki, the local
ethics committee of the University of Cologne has approved the
research protocol. All patients gave their written informed consent.
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The cohort of 145 subjects was composed of patients with recent
onset (,10 days, mean 5.860.5 days) AF (AF-group; n=87) and
matched patients without documented and subjective history of AF
(control group;n=58; Figure1).Patientswith AFwere atageabove
18 years and revealed at least one of the additional comorbidities:
coronary heart disease (CHD), dilated cardiomyopathy (DCM) with
reduced left ventricular ejection fraction (,50%), heart failure (.
NYHA II) or a PROCAM-score above 41 [17]. In all patients with
AF transesophageal echocardiography was performed to exclude
the presence of intracardiac thrombi. Routine transthoracic
echocardiography was performed to measure cardiac dimensions
and asses valvular, left and right ventricular function.
Matched patients in the control group were admitted to our
hospital with acute myocardial infarction for percutaneous
coronary intervention, without any history of AF.
Sinus rhythm cardioversion
For pharmacological cardioversion patients with AF received
oral flecainide 300 mg. A successful cardioversion was defined as
sinus rhythm restoration within the first 6 hours after flecainide
intake. After 12-h ECG monitoring had confirmed the persistence
of a stable sinus rhythm. Patients in which flecainide did not
restore sinus rhythm underwent electrical cardioversion (data not
shown). At four weeks the persistence of sinus rhythm was
controlled.
Genotyping
Genomic DNA was extracted from blood of subjects by
standard techniques [18]. Polymorphism detection was performed
like previously described [10]. Briefly, DNA was amplified by
polymerase chain reaction and subjected to enzymatic restriction
analysis by BsmF1 for the position 389 and Eco01091 for the
position 49 [10,12]. Genotyping was performed blindly to all other
data.
Statistical analysis
All variables were tested for normal distribution with the
Kolmogorov-Smirnov test. Continuous variables are expressed as
means 6 standard error of the mean. Comparison of 2 means was
performed with the t test for normally distributed variables and the
Mann-Whitney U test for non-Gaussian variables. Chi-square test
was used for nonparametric comparisons. All statistical tests were
2-tailed, and p,0.05 was considered statistically significant.
Figure 1. Study flow chart. Allele frequencies of different SNPs at position 389 and 49. The Gly49Gly variant was not present in any patient. All
seven patients with Gly389Gly were homozygous for Ser49Ser.
doi:10.1371/journal.pone.0011421.g001
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Patient Characteristics
The mean age of participants with AF was 67.861.3 years (71%
men). Genotyping revealed a prevalence of homozygous patients
for Arg389Arg of 41.4% (n=36), heterozygous for Arg389Gly of
50.6% (n=44) and homozygous for Gly389Gly of 8% (n=7). 59
patients (67.8%) with AF were homozygous for serine at position
49 (Ser49Ser) and 28 patients (32.2%) heterozygous for Ser49Gly.
The Gly49Gly genotype was not present in any patient (Figure 1).
Baseline characteristics were similar in all variants (Table 1). In
particular the calculated PROCAM-score, serum potassium and
sodium concentrations were not significantly divergent between
different allele carriers. Baseline heart rate during AF was
significantly higher in patients with the Arg389Arg genotype with
110.762.7 bpm versus 104.862.4 bpm in patients with Arg389-
Gly and 96.965.8 bpm in Gly389Gly carriers (p=0.03). In
patients homozygous to Arg389Arg the heart rate was not
influenced by Ser49Ser (n=32; 110.863.0 bpm; p=ns) and
Ser49Gly (n=4; 110.064.1 bpm; p=ns). The resting heart rate
was not modified in the same manner by Ser49Ser or Ser49Gly
polymorphism in patients heterozygous for Arg389Gly (Ser49Ser:
n=20; 102.562.9 bpm; Ser49Gly: n=24; 106.763.0 bpm;
p=ns). In patients homozygous for Gly389Gly only the Ser49Ser
variant was present.
Echocardiographic assessment revealed similar left atrial and
ventricular diameters and left ventricular ejection fraction in all
allele groups (Table 2). There was a trend towards larger diastolic
interventricular septum diameter (IVSDD) in patients with
Arg389Arg alleles (11.460.2 mm; Arg389Arg-Ser49Ser:
11.460.3 mm; Arg389Arg-Ser49Gly 11.360.3 mm) versus
Arg389Gly (10.960.2 mm; Arg389Gly-Ser49Ser 11.263.8 mm;
Arg389Gly-Ser49Gly 10.760.2 mm) and Gly389Gly alleles
(10.160.3 mm; p=0.05 between P389 polymorphisms). The
SNP49 variants did not significantly modify the IVSDD.
Cardiovascular medication was similar in groups with different
polymorphisms (Table 3).
b1AR Profile and Flecainide Success
The overall cardioversion success rate after oral flecainide
300 mg was 39% (34/87). The significantly highest rate of sinus
rhythm restoration of 55.5% (20/36) was found in patients
homozygous to Arg389Arg polymorphism (OR 3.30; 95% CI;
1.34–8.13; p=0.003; Figure 2).
In patients with Arg389Gly alleles flecainide was slightly less
effective with a cardioversion rate of 29.5% (13/44; OR 0.44; 95%













Women/Men (%) 25/62 (29/71) 8/28 (22/78) 14/30 (31/69) 3/4 (43/57) 18/41 (31/29) 7/21 (25/75)
Age 67.861.3 67.162.1 67.761.8 72.062.6 67.162.1 69.363.8
BMI 26.660.4 27.260.5 26.460.5 24.861.0 26.460.7 27.060.5
Heart rate per minute 106.661.7 110.762.7* 104.862.4 96.965.8 107.461.8 104.962.4
PROCAM-Score 44.460.5 44.260.7 44.960.8 42.861.3 44.460.7 44.460.5
Hypertension (%) 47 (54) 17 (47) 25 (57) 5 (71) 33 (56) 14 (50)
CAD (%) 32 (37) 13 (36) 18 (41) 1 (14) 22 (37) 10 (36)
Myocardial infarction (%) 17 (20) 9 (25) 8 (18) 0 (0) 13 (22) 4 (14)
LVEF ,40% 22 (25) 10 (28) 11 (25) 1 (14) 16 (27) 6 (21)
CABG (%) 7 (8) 4 (11) 3 (7) 0 (0) 5 (8) 2 (7)
Serum sodium (mmol/l) 137.860.5 137.160.9 138.660.5 136.561.0 138.160.4 137.360.5
Serum potassium (mmol/I) 4.160.1 4.160.1 4.160.1 4.360.3 4.060.1 4.360.4
BMI indicates body mass index, CAD indicates coronary artery disease, LVEF indicates left ventricular ejection fraction, CABG indicates coronary artery bypass grafting.
*p,0.05 vs. other variants.
doi:10.1371/journal.pone.0011421.t001













LA (mm) 46.760.8 47.661.5 46.061.1 47.161.4 47.661.0 44.761.5
LVEDD (mm) 51.560.7 51.460.9 52.060.9 49.462.5 50.760.7 53.361.3
IVSDD (mm) 11.160.2 11.460.2# 10.960.2 10.160.3 11.260.2 10.860.2
LVEF (%) 56.861.5 55.662.5 57.062.1 62.165.0 58.661.6 53.063.0
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Gly389Gly polymorphism in one of seven patients sinus rhythm
could be restored (OR 0.24; 95% CI 0.03–2.07; p=0.17). The
SNP49 variants alone were not associated with the flecainide
success in cardioversion. The combination of different SNP389
and SNP49 variants revealed the highest rate for a successful
cardioversion with flecainide in patients with the genotype
Arg389Arg independently to the coexisting SNP49 variants













Beta-blocker (%) 79 (91) 34 (94) 39 (89) 6 (86) 53 (89) 26 (93)
ACE-Inhibitor (%) 27 (31) 12 (33) 13 (30) 2 (29) 19 (32) 8 (29)
ARB (%) 22 (25) 10 (28) 9 (20) 3 (43) 15 (25) 7 (25)
Statin (%) 38 (44) 17 (47) 19 (43) 2 (29) 25 (42) 13 (46)
ACE indicates angiotensin converting enzyme, ARB indicates angiotensin receptor blocker.
doi:10.1371/journal.pone.0011421.t003
Figure 2. Success of flecainide-induced cardioversion in different b1AR genotypes, A, P389 polymorphism, B, P49 polymor-
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cardioversion was associated with the genotype Arg389Gly-
Ser49Gly (OR 0.31; 95% CI 0.10–0.93; p=0.03).
Mean heart rate of patients with successful cardioversion was
during AF higher versus patients without sinus rhythm restoration,
although statistical significance was not reached (108.064.9 bpm
vs. 99.463.3 bpm; p=ns).
All patients in which pharmacological cardioversion failed
underwent successful electrical cardioversion. At four weeks
follow-up two patients showed a relapse of atrial fibrillation.
b1AR Polymorphism and Risk of Atrial Fibrillation
To identify whether the risk for AF is linked to a specific b1AR
polymorphism, we compared the relative allele frequencies in
patients with AF (AF-group; n=87) to patients with no history of
AF (control-group; n=58).
This comparison revealed quite similar SNP389 allele distribu-
tions in patients with AF versus control-group (Arg389Arg: 41.4%
AF-group vs. 48.3% control-group, p=ns; Arg389Gly: 50.6% AF-
group vs. 46.6% control-group, p=ns; Gly389Gly: 8.0% AF-
group vs. 5.1%, p=ns; Figure 3A). The prevalence of the Ser49Ser
polymorphism was tendentiously higher in patients without AF
versus those with AF (32.2% vs. 17.2%; p=0.045; Figure 3B).
Conversely, Ser49Gly genotype was slightly more common in
patients with than without AF (73.7% vs. 26.3%; p=0.045). The
combination of both SNPs revealed that the prevalence of the
Arg389Gly-Ser49Gly genotype was significantly higher in patients
with versus without AF (27.6% versus 5.2%; p=0.001; Figure 3C).
Thus, a hazard ratio of 6.98 for AF in patients with the
Arg389Gly-Ser49Gly genotype was calculated (95% CI, 1.99–
24.46; p,0.001).
Discussion
The Arg389Gly polymorphism has been shown to be associated
with heart failure, acute myocardial infarction, hypertension and
left ventricular remodeling in response to beta- blockade
[19,20,21].
We found that the Arg389Arg polymorphism was strongly
associated with a higher efficiency of flecainide action in patients
with AF. Reported different affinity of b1AR SNP389 variants to
catecholamines may explain the underlying mechanism of this
observation [11,22,23]. In vitro experiments have demonstrated
that the Arg389Arg genotype is a gain-of-function variant with
enhanced coupling to Gs protein, following a slightly elevated
basal and three- to four-fold higher adenylate cyclase activity than
Gly389 variants [10]. Isoproterenol-stimulation enhances Gs
protein activation and adrenergic-mediated reduction of sodium
current [24]. This accessory reduction of sodium influx may
potentiate the flecainide induced-blockade of INa (Figure 4).
Compared to more healthy subjects we noticed a poorer
cardioversion rate in population with organic heart diseases
despite the expected higher susceptibility to flecainide due to
elevated catecholamine concentrations in these patients
[1,2,25,26]. But contrarily, diseased cardiomyocytes promote AF
due to complex electrical and structural remodeling [27,28,29,30].
These changes may outbalance the supposed increased antiar-
rhythmic effects of flecainide. Chronic treatment with flecainide
has been reported to be harmful, particularly in patients with
structural heart diseases and myocardial infarction [31]. Higher
serum catecholamine concentrations in patients with cardiovas-
cular diseases may have augmented the b1AR-induced INa
blockade and the proarrhythmic effects of flecainide, especially
in patients with vulnerable myocardium and the Arg389Arg
genotype [25,26,32,33,34,35].
Newer antiarrhythmic agents like vernakalant and dronedarone
with sodium channel blocking attribute may be similarly
influenced by b1AR variants [36,37].
Resting heart rate has been associated with Arg389Gly variants
[38,39]. Concordantly, we observed during AF significantly higher
ventricular heart rates in homozygous patients for the arginine
allele and the lowest heart rate in patients homozygous for the
glycine variant (heart rate Arg389Arg.Arg389Gly.Gly389Gly).
This may have clinical consequences and patients with Arg389Arg
genotype may need intensified beta-blocker treatment.
The interventricular septum thickness was larger in patients
with Arg389Arg than in carriers of other variants. This may be
explained due to elevated catecholamine impact on cardiomyo-
cytes in this genotype and enhanced hypertrophy signaling [40].
The b1AR SNP49 polymorphism itself was not associated with
functional effects of flecainide. But in combination with the P389
polymorphism flecainide was most effective in Arg389Arg-
Table 4. Association between different genotypes and the success of flecainide-induced cardioversion.
Flecainide Success OR 95% CI p
Arg389Arg (n=36) 20 (55.5%) 3.30 1.3428.13 0.003
Ser49Ser (n=32) 17 (53.1%) 2.53 1.0326.23 0.04
Ser49Gly (n=4) 3 (75.0%) 5.03 0.50250.52 0.14
Gly49Gly (n=0) - - - -
Arg389Gly (n=44) 13 (29.5%) 0.44 0.1821.06 0.066
Ser49Ser (n=20) 8 (40.0%) 1.05 0.3822.92 0.93
Ser49Gly (n=24) 5 (20.8%) 0.31 0.1020.93 0.03
Gly49Gly (n=0) - - - -
Gly389Gly (n=7) 1 (14.3%) 0.24 0.0322.07 0.17
Ser49Ser (n=7) 1 (14.3%) 0.24 0.0322.07 0.17
Ser49Gly (n=0) - - - -
Gly49Gly (n=0) - - - -
doi:10.1371/journal.pone.0011421.t004
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genotype. This finding is supported by previous reports that the
SNP49 variants have not an effect on the adenyl cyclase activity
and position 389, but not 49, obviously determines the functional
responsiveness of b1AR, and P49 may only play a modulating role
[9]. The genotype Arg389Arg-Ser49Gly may need higher
flecainide concentrations for successful cardioversion.
In the present study the SNP389 b1AR genotype alone was not,
and the Ser49Gly genotype slightly associated with the AF
prevalence. But in combination of both SNPs, the genotype
Arg389Gly-Ser49Gly was associated with an almost 7-fold higher
risk for AF than other genotypes. Despite the limited sample size in
our cohort, this finding confirms a recent report that the Ser49Gly
variant may be associated with AF [41]. Further studies are
needed to figure out the causal explanation for this supposed
genetic determination of AF.
The present investigation provides more insight into the
potential influences of b1AR polymorphism on antiarrhythmic
drug action, which are currently underestimated. Our results
indicate that genetic testing might help identifying patients at
elevated risk for AF. When this observation is confirmed in larger
cohorts, preventive strategies in these patients might be helpful.
Further studies with genetic testing may help to identify patients
with organic heart diseases in whom a differential antiarrhythmic
therapy might be indicated. Newer antiarrhythmic drugs may also
interfere with the b1AR polymorphism.
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